Expert wants anti-cancer drug subsidised

PUBLISHED : Wednesday, 14 May, 2008, 12:00am
UPDATED : Wednesday, 14 May, 2008, 12:00am

A University of Hong Kong cancer expert wants a newly registered anti-breast cancer drug put on the Hospital Authority's formulary. Daniel Chua Tsin-tien, associate professor of HKU's clinical oncology department, said that tests using the drug, lapatinib, combined with capecitabine, showed an 88 per cent chance of patients with last-stage HER2 breast cancer controlling the disease. There was a 35 per cent chance tumours would shrink in size by more than half.


Send to a friend

To forward this article using your default email client (e.g. Outlook), click here.

Enter multiple addresses separated by commas(,)

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Related topics